Frontiers of Science

May 25^th at 12:00
On-site event
Presidentti auditorium, BioCity
Spring 2023 program

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Harvard Medical School, USA
Challenges in molecularly targeted treatment of lung cancer
Host: Klaus Elenius (klaele@utu.fi)

Coffee and sandwich served at 11:45

Six students and early-career postdocs are welcome to have a lunch and discuss with Prof. Jänne after the seminar. This is a great possibility to learn hosting skills in friendly environment and create connections for future. Every student are welcome to join, in spite of which research group they belong to. BioCity Turku will offer the lunch.

If you got interested, please send an email to biocityturku@bioscience.fi

The Jänne Lab’s research integrates bench-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. The Lab’s main research interest centers on understanding and translating the therapeutic importance of oncogenic alterations found in lung cancer. Dr. Jänne is a translational thoracic medical oncologist at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. He is the director of the Lowe Center for Thoracic Oncology and the scientific co-director of the Belfer Center for Applied Cancer Sciences.

Selected publications

Hartmaier RJ, Markovets AA, Ahn MJ, … , Cantarini M, Jänne PA. 2023. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 13:98-113

Kobayashi Y, Oxnard GR, Cohen EF, Mahadevan NR, … , Sholl LM, Jänne PA. 2022. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun 13:5614

To C, Beyett TS, Jang J, Feng WW, …, Eck MJ, Gray NS, Jänne PA. 2022. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 3:402-417

Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. 2022. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature 603:335-342

Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. 2022. Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer. Cancer Discov. 12:74-89

General information

• You can download all spring 2023 FoS-seminars in your calendar from here: https://seafile.utu.fi/d/4a0b831f23ef420786b0/
• Registration is not needed for the on-site seminars
• Participation list is circulated in the audience
• If you are a student and later wish to get a certificate of attendance from the Frontier of Science seminars, please print out this seminar diary and after the seminar ask the BioCity coordinator to sign it
• Please note that any audio or video recording of the seminars is strictly forbidden.